PDF herunterladen
Thromb Haemost 2018; 118(09): 1656-1667
DOI: 10.1055/s-0038-1667337
Atherosclerosis and Ischaemic Disease
Georg Thieme Verlag KG Stuttgart · New York

Genotype-Phenotype Association and Impact on Outcomes following Guided De-Escalation of Anti-Platelet Treatment in Acute Coronary Syndrome Patients: The TROPICAL-ACS Genotyping Substudy

Lisa Gross
1   Department of Cardiology, LMU München, Munich, Germany
,
Dietmar Trenk
2   Department of Cardiology and Angiology II, University Heart Centre Freiburg, University of Freiburg, Bad Krozingen, Germany
,
Claudius Jacobshagen
3   Department of Cardiology and Pneumology, Heart Centre, Georg-August-University Göttingen, Göttingen, Germany
,
Anne Krieg
1   Department of Cardiology, LMU München, Munich, Germany
,
Meinrad Gawaz
4   Department of Cardiology and Cardiovascular Disease, University Hospital Tübingen, University of Tübingen, Tübingen, Germany
,
Steffen Massberg
1   Department of Cardiology, LMU München, Munich, Germany
5   DZHK (German Centre for Cardiovascular Research), Partner Site Munich Heart Alliance, Munich, Germany
,
Monika Baylacher
1   Department of Cardiology, LMU München, Munich, Germany
,
Daniel Aradi
6   Heart Centre Balatonfüred and Heart and Vascular Centre, Semmelweis University, Budapest, Hungary
,
Fabian Stimpfle
4   Department of Cardiology and Cardiovascular Disease, University Hospital Tübingen, University of Tübingen, Tübingen, Germany
,
Julia Hromek
2   Department of Cardiology and Angiology II, University Heart Centre Freiburg, University of Freiburg, Bad Krozingen, Germany
,
Anja Vogelgesang
3   Department of Cardiology and Pneumology, Heart Centre, Georg-August-University Göttingen, Göttingen, Germany
,
Martin Hadamitzky
7   Department of Radiology, Deutsches Herzzentrum München, Technical University of Munich, München, Germany
,
Dirk Sibbing   *
1   Department of Cardiology, LMU München, Munich, Germany
5   DZHK (German Centre for Cardiovascular Research), Partner Site Munich Heart Alliance, Munich, Germany
,
Tobias Geisler   *
4   Department of Cardiology and Cardiovascular Disease, University Hospital Tübingen, University of Tübingen, Tübingen, Germany
› Institutsangaben Funding TROPICAL-ACS is an independent, investigator-initiated trial with an academic sponsor (Klinikum der Universität München). The trial was financially supported by a research grant from Roche Diagnostics (Rotkreuz, Switzerland) and a research grant from the German Centre for Cardiovascular Research (DZHK). Prasugrel purchase, drug delivery and related logistics were kindly supported by Eli Lilly and Company and Daiichi Sankyo Company. Funders of this study had no role in study design, collection of data and data analysis, or writing of the manuscript.
Weitere Informationen

Publikationsverlauf

06. Mai 2018

21. Juni 2018

Publikationsdatum:
13. August 2018 (online)

   Lizenzen und Reprints

Abstract

Background Phenotype-guided de-escalation (PGDE) of P2Y12-inhibitor treatment with an early switch from prasugrel to clopidogrel was identified as an effective alternative treatment strategy in acute coronary syndrome (ACS) patients undergoing percutaneous coronary intervention (PCI). The Testing Responsiveness to Platelet Inhibition on Chronic Antiplatelet Treatment for Acute Coronary Syndromes (TROPICAL-ACS) Genotyping Substudy aimed to investigate whether CYP2C19 genotypes correlate with on-treatment platelet reactivity (PR) in ACS patients treated with clopidogrel or prasugrel and thus might be useful for guidance of early de-escalation of anti-platelet treatment.

Methods and Results A total of 603 ACS consecutive patients were enrolled in four centres (23.1% of the overall TROPICAL-ACS population). Rapid genotyping (Spartan RX) for CYP2C19*2, *3 and *17 alleles was performed. Associations between PR and the primary and secondary endpoints of the TROPICAL-ACS trial and CYP2C19*2 and CYP2C19*17 carrier status were evaluated.

For the PGDE group, the on-clopidogrel PR significantly differed across CYP2C19*2 (p < 0.001) and CYP2C19*17 genotypes (p = 0.05). Control group patients were not related (p = 0.90, p = 0.74) to on-prasugrel PR. For high PR versus non-high PR patients within the PGDE group, significant differences were observed for the rate of CYP2C19*2 allele carriers (43% vs. 28%, p = 0.007).

Conclusion CYP2C19*2 and CYP2C19*17 carrier status correlates with PR in ACS patients treated with clopidogrel and thus might be useful for pre-selecting patients who will and who may not be suitable for PGDE of anti-platelet treatment. Regarding phenotype-guided treatment, we did not observe added benefit of genotyping to predict ischaemic and bleeding risk in patients who underwent a PGDE approach.

Clinical Trial Registration URL: https//www.clinicaltrials.gov. Unique Identifier: NCT: 01959451.

Keywords

acute coronary syndrome - genotyping - platelets - thrombosis - bleeding - cytochrome P450 (CYP) 2C19

* Dirk Sibbing and Tobias Geisler are senior authors who contributed equally to the work.


 

  • References

  • 1 Amsterdam EA, Wenger NK, Brindis RG. , et al. 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2014; 64 (24) e139-e228
    CrossrefPubMedGoogle Scholar
  • 2 Roffi M, Patrono C, Collet JP. , et al; ESC Scientific Document Group. 2015 ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC). Eur Heart J 2016; 37 (03) 267-315
    Google Scholar
  • 3 Ibanez B, James S, Agewall S. , et al. ESC Scientific Document Group. 2017 ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: the Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J 2018; 39 (02) 119-177
    CrossrefPubMedGoogle Scholar
  • 4 Zettler ME, Peterson ED, McCoy LA. , et al; TRANSLATE-ACS Investigators. Switching of adenosine diphosphate receptor inhibitor after hospital discharge among myocardial infarction patients: insights from the Treatment with Adenosine Diphosphate Receptor Inhibitors: Longitudinal Assessment of Treatment Patterns and Events after Acute Coronary Syndrome (TRANSLATE-ACS) observational study. Am Heart J 2017; 183: 62-68
    CrossrefPubMedGoogle Scholar
  • 5 De Luca L, D'Ascenzo F, Musumeci G. , et al. Incidence and outcome of switching of oral platelet P2Y12 receptor inhibitors in patients with acute coronary syndromes undergoing percutaneous coronary intervention: the SCOPE registry. EuroIntervention 2017; 13 (04) 459-466
    CrossrefPubMedGoogle Scholar
  • 6 Motovska Z, Hlinomaz O, Miklik R. , et al; PRAGUE-18 Study Group. Prasugrel versus ticagrelor in patients with acute myocardial infarction treated with primary percutaneous coronary intervention: multicenter randomized PRAGUE-18 study. Circulation 2016; 134 (21) 1603-1612
    CrossrefPubMedGoogle Scholar
  • 7 Déry JP, Mehta SR, Fisher HN. , et al; Canadian Observational AntiPlatelet sTudy (COAPT) Investigators. Baseline characteristics, adenosine diphosphate receptor inhibitor treatment patterns, and in-hospital outcomes of myocardial infarction patients undergoing percutaneous coronary intervention in the prospective Canadian Observational AntiPlatelet sTudy (COAPT). Am Heart J 2016; 181: 26-34
    CrossrefPubMedGoogle Scholar
  • 8 Angiolillo DJ, Rollini F, Storey RF. , et al. International expert consensus on switching platelet P2Y12 receptor-inhibiting therapies. Circulation 2017; 136 (20) 1955-1975
    CrossrefPubMedGoogle Scholar
  • 9 Gurbel PA, Bliden KP, Hiatt BL, O'Connor CM. Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity. Circulation 2003; 107 (23) 2908-2913
    CrossrefPubMedGoogle Scholar
  • 10 Mega JL, Simon T, Collet JP. , et al. Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis. JAMA 2010; 304 (16) 1821-1830
    CrossrefPubMedGoogle Scholar
  • 11 Sibbing D, Stegherr J, Latz W. , et al. Cytochrome P450 2C19 loss-of-function polymorphism and stent thrombosis following percutaneous coronary intervention. Eur Heart J 2009; 30 (08) 916-922
    PubMedGoogle Scholar
  • 12 Shuldiner AR, O'Connell JR, Bliden KP. , et al. Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. JAMA 2009; 302 (08) 849-857
    CrossrefPubMedGoogle Scholar
  • 13 Mega JL, Close SL, Wiviott SD. , et al. Cytochrome p-450 polymorphisms and response to clopidogrel. N Engl J Med 2009; 360 (04) 354-362
    CrossrefPubMedGoogle Scholar
  • 14 Collet JP, Hulot JS, Pena A. , et al. Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study. Lancet 2009; 373 (9660): 309-317
    CrossrefPubMedGoogle Scholar
  • 15 Simon T, Verstuyft C, Mary-Krause M. , et al; French Registry of Acute ST-Elevation and Non-ST-Elevation Myocardial Infarction (FAST-MI) Investigators. Genetic determinants of response to clopidogrel and cardiovascular events. N Engl J Med 2009; 360 (04) 363-375
    CrossrefPubMedGoogle Scholar
  • 16 Scott SA, Sangkuhl K, Stein CM. , et al; Clinical Pharmacogenetics Implementation Consortium. Clinical Pharmacogenetics Implementation Consortium guidelines for CYP2C19 genotype and clopidogrel therapy: 2013 update. Clin Pharmacol Ther 2013; 94 (03) 317-323
    Google Scholar
  • 17 Cavallari LH. Personalizing antiplatelet prescribing using genetics for patients undergoing percutaneous coronary intervention. Expert Rev Cardiovasc Ther 2017; 15 (08) 581-589
    CrossrefPubMedGoogle Scholar
  • 18 Sibbing D, Koch W, Gebhard D. , et al. Cytochrome 2C19*17 allelic variant, platelet aggregation, bleeding events, and stent thrombosis in clopidogrel-treated patients with coronary stent placement. Circulation 2010; 121 (04) 512-518
    CrossrefPubMedGoogle Scholar
  • 19 Wallentin L, James S, Storey RF. , et al; PLATO investigators. Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial. Lancet 2010; 376 (9749): 1320-1328
    CrossrefPubMedGoogle Scholar
  • 20 Zabalza M, Subirana I, Sala J. , et al. Meta-analyses of the association between cytochrome CYP2C19 loss- and gain-of-function polymorphisms and cardiovascular outcomes in patients with coronary artery disease treated with clopidogrel. Heart 2012; 98 (02) 100-108
    PubMedGoogle Scholar
  • 21 Li Y, Tang HL, Hu YF, Xie HG. The gain-of-function variant allele CYP2C19*17: a double-edged sword between thrombosis and bleeding in clopidogrel-treated patients. J Thromb Haemost 2012; 10 (02) 199-206
    CrossrefPubMedGoogle Scholar
  • 22 Giusti B, Gori AM, Marcucci R. , et al. Relation of cytochrome P450 2C19 loss-of-function polymorphism to occurrence of drug-eluting coronary stent thrombosis. Am J Cardiol 2009; 103 (06) 806-811
    CrossrefPubMedGoogle Scholar
  • 23 Trenk D, Hochholzer W, Fromm MF. , et al. Cytochrome P450 2C19 681G>A polymorphism and high on-clopidogrel platelet reactivity associated with adverse 1-year clinical outcome of elective percutaneous coronary intervention with drug-eluting or bare-metal stents. J Am Coll Cardiol 2008; 51 (20) 1925-1934
    CrossrefPubMedGoogle Scholar
  • 24 Hulot JS, Collet JP, Silvain J. , et al. Cardiovascular risk in clopidogrel-treated patients according to cytochrome P450 2C19*2 loss-of-function allele or proton pump inhibitor coadministration: a systematic meta-analysis. J Am Coll Cardiol 2010; 56 (02) 134-143
    CrossrefPubMedGoogle Scholar
  • 25 Sorich MJ, Rowland A, McKinnon RA, Wiese MD. CYP2C19 genotype has a greater effect on adverse cardiovascular outcomes following percutaneous coronary intervention and in Asian populations treated with clopidogrel: a meta-analysis. Circ Cardiovasc Genet 2014; 7 (06) 895-902
    PubMedGoogle Scholar
  • 26 Bauer T, Bouman HJ, van Werkum JW, Ford NF, ten Berg JM, Taubert D. Impact of CYP2C19 variant genotypes on clinical efficacy of antiplatelet treatment with clopidogrel: systematic review and meta-analysis. BMJ 2011; 343: d4588
    CrossrefPubMedGoogle Scholar
  • 27 Holmes MV, Perel P, Shah T, Hingorani AD, Casas JP. CYP2C19 genotype, clopidogrel metabolism, platelet function, and cardiovascular events: a systematic review and meta-analysis. JAMA 2011; 306 (24) 2704-2714
    CrossrefPubMedGoogle Scholar
  • 28 Jang JS, Cho KI, Jin HY. , et al. Meta-analysis of cytochrome P450 2C19 polymorphism and risk of adverse clinical outcomes among coronary artery disease patients of different ethnic groups treated with clopidogrel. Am J Cardiol 2012; 110 (04) 502-508
    CrossrefPubMedGoogle Scholar
  • 29 Liu YP, Hao PP, Zhang MX. , et al. Association of genetic variants in CYP2C19 and adverse clinical outcomes after treatment with clopidogrel: an updated meta-analysis. Thromb Res 2011; 128 (06) 593-594
    CrossrefPubMedGoogle Scholar
  • 30 Viviani Anselmi C, Briguori C, Roncarati R. , et al. Routine assessment of on-clopidogrel platelet reactivity and gene polymorphisms in predicting clinical outcome following drug-eluting stent implantation in patients with stable coronary artery disease. JACC Cardiovasc Interv 2013; 6 (11) 1166-1175
    CrossrefPubMedGoogle Scholar
  • 31 Cresci S, Depta JP, Lenzini PA. , et al. Cytochrome p450 gene variants, race, and mortality among clopidogrel-treated patients after acute myocardial infarction. Circ Cardiovasc Genet 2014; 7 (03) 277-286
    CrossrefPubMedGoogle Scholar
  • 32 Stimpfle F, Geisler T. Impact of tailored anti-P2Y12 therapies in acute coronary syndromes. Pharmacogenomics 2015; 16 (05) 493-499
    CrossrefPubMedGoogle Scholar
  • 33 Cavallari LH, Franchi F, Rollini F. , et al. Clinical implementation of rapid CYP2C19 genotyping to guide antiplatelet therapy after percutaneous coronary intervention. J Transl Med 2018; 16 (01) 92
    CrossrefPubMedGoogle Scholar
  • 34 Sibbing D, Aradi D, Jacobshagen C. , et al; TROPICAL-ACS Investigators. A randomised trial on platelet function-guided de-escalation of antiplatelet treatment in ACS patients undergoing PCI. Rationale and design of the Testing Responsiveness to Platelet Inhibition on Chronic Antiplatelet Treatment for Acute Coronary Syndromes (TROPICAL-ACS) Trial. Thromb Haemost 2017; 117 (01) 188-195
    Artikel in Thieme ConnectPubMedGoogle Scholar
  • 35 Sibbing D, Aradi D, Jacobshagen C. , et al; TROPICAL-ACS Investigators. Guided de-escalation of antiplatelet treatment in patients with acute coronary syndrome undergoing percutaneous coronary intervention (TROPICAL-ACS): a randomised, open-label, multicentre trial. Lancet 2017; 390 (10104): 1747-1757
    CrossrefPubMedGoogle Scholar
  • 36 Aradi D, Kirtane A, Bonello L. , et al. Bleeding and stent thrombosis on P2Y12-inhibitors: collaborative analysis on the role of platelet reactivity for risk stratification after percutaneous coronary intervention. Eur Heart J 2015; 36 (27) 1762-1771
    CrossrefPubMedGoogle Scholar
  • 37 Roberts JD, Wells GA, Le May MR. , et al. Point-of-care genetic testing for personalisation of antiplatelet treatment (RAPID GENE): a prospective, randomised, proof-of-concept trial. Lancet 2012; 379 (9827): 1705-1711
    CrossrefPubMedGoogle Scholar
  • 38 Tantry US, Bonello L, Aradi D. , et al; Working Group on On-Treatment Platelet Reactivity. Consensus and update on the definition of on-treatment platelet reactivity to adenosine diphosphate associated with ischemia and bleeding. J Am Coll Cardiol 2013; 62 (24) 2261-2273
    CrossrefPubMedGoogle Scholar
  • 39 Thygesen K, Alpert JS, Jaffe AS. , et al; Joint ESC/ACCF/AHA/WHF Task Force for Universal Definition of Myocardial Infarction; Authors/Task Force Members Chairpersons; Biomarker Subcommittee; ECG Subcommittee; Imaging Subcommittee; Classification Subcommittee; Intervention Subcommittee; Trials & Registries Subcommittee; Trials & Registries Subcommittee; Trials & Registries Subcommittee; Trials & Registries Subcommittee; ESC Committee for Practice Guidelines (CPG); Document Reviewers. Third universal definition of myocardial infarction. J Am Coll Cardiol 2012; 60 (16) 1581-1598
    CrossrefPubMedGoogle Scholar
  • 40 Mehran R, Rao SV, Bhatt DL. , et al. Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium. Circulation 2011; 123 (23) 2736-2747
    CrossrefPubMedGoogle Scholar
  • 41 Rodriguez S, Gaunt TR, Day IN. Hardy-Weinberg equilibrium testing of biological ascertainment for Mendelian randomization studies. Am J Epidemiol 2009; 169 (04) 505-514
    CrossrefPubMedGoogle Scholar
  • 42 Rollini F, Franchi F, Angiolillo DJ. Switching P2Y12-receptor inhibitors in patients with coronary artery disease. Nat Rev Cardiol 2016; 13 (01) 11-27
    CrossrefPubMedGoogle Scholar
  • 43 Cuisset T, Deharo P, Quilici J. , et al. Benefit of switching dual antiplatelet therapy after acute coronary syndrome: the TOPIC (timing of platelet inhibition after acute coronary syndrome) randomized study. Eur Heart J 2017; 38 (41) 3070-3078
    CrossrefPubMedGoogle Scholar
  • 44 Sherwood MW, Wiviott SD, Peng SA. , et al. Early clopidogrel versus prasugrel use among contemporary STEMI and NSTEMI patients in the US: insights from the National Cardiovascular Data Registry. J Am Heart Assoc 2014; 3 (02) e000849
    PubMedGoogle Scholar
  • 45 Bergmeijer TO, Janssen PW, Schipper JC. , et al. CYP2C19 genotype-guided antiplatelet therapy in ST-segment elevation myocardial infarction patients-rationale and design of the Patient Outcome after primary PCI (POPular) Genetics study. Am Heart J 2014; 168 (01) 16-22
    CrossrefPubMedGoogle Scholar
  • 46 Wirth F, Zahra G, Xuereb RG, Barbara C, Fenech A, Azzopardi LM. Comparison of a rapid point-of-care and two laboratory-based CYP2C19*2 genotyping assays for personalisation of antiplatelet therapy. Int J Clin Pharm 2016; 38 (02) 414-420
    CrossrefPubMedGoogle Scholar
  • 47 Erlinge D, James S, Duvvuru S. , et al. Clopidogrel metaboliser status based on point-of-care CYP2C19 genetic testing in patients with coronary artery disease. Thromb Haemost 2014; 111 (05) 943-950
    Artikel in Thieme ConnectPubMedGoogle Scholar
  • 48 Weitzel KW, Elsey AR, Langaee TY. , et al. Clinical pharmacogenetics implementation: approaches, successes, and challenges. Am J Med Genet C Semin Med Genet 2014; 166C (01) 56-67
    PubMedGoogle Scholar
  • 49 Shuldiner AR, Palmer K, Pakyz RE. , et al. Implementation of pharmacogenetics: the University of Maryland Personalized Anti-platelet Pharmacogenetics Program. Am J Med Genet C Semin Med Genet 2014; 166C (01) 76-84
    PubMedGoogle Scholar
  • 50 Peterson JF, Field JR, Unertl KM. , et al. Physician response to implementation of genotype-tailored antiplatelet therapy. Clin Pharmacol Ther 2016; 100 (01) 67-74
    CrossrefPubMedGoogle Scholar
  • 51 Lee JA, Lee CR, Reed BN. , et al. Implementation and evaluation of a CYP2C19 genotype-guided antiplatelet therapy algorithm in high-risk coronary artery disease patients. Pharmacogenomics 2015; 16 (04) 303-313
    CrossrefPubMedGoogle Scholar
  • 52 Harada S, Zhou Y, Duncan S. , et al. Precision medicine at the University of Alabama at Birmingham: laying the foundational processes through implementation of genotype-guided antiplatelet therapy. Clin Pharmacol Ther 2017; 102 (03) 493-501
    CrossrefPubMedGoogle Scholar
  • 53 Cavallari LH, Lee CR, Beitelshees AL. , et al. IGNITE Network. Multisite investigation of outcomes with implementation of CYP2C19 genotype-guided antiplatelet therapy after percutaneous coronary intervention. JACC Cardiovasc Interv 2018; 11 (02) 181-191
    CrossrefPubMedGoogle Scholar
  • 54 Cavallari LH, Beitelshees AL, Blake KV. , et al; The IGNITE Pharmacogenetics Working Group. The IGNITE Pharmacogenetics Working Group: an opportunity for building evidence with pharmacogenetic implementation in a real-world setting. Clin Transl Sci 2017; 10 (03) 143-146
    CrossrefPubMedGoogle Scholar
  • 55 Empey PE, Stevenson JM, Tuteja S. , et al; IGNITE Network. Multi-site investigation of strategies for the implementation of CYP2C19 genotype-guided antiplatelet therapy. Clin Pharmacol Ther 2017; DOI: 10.1002/cpt.1006.
    PubMedGoogle Scholar
  • 56 Holmes Jr DR, Dehmer GJ, Kaul S, Leifer D, O'Gara PT, Stein CM. ACCF/AHA clopidogrel clinical alert: approaches to the FDA “boxed warning”: a report of the American College of Cardiology Foundation Task Force on clinical expert consensus documents and the American Heart Association endorsed by the Society for Cardiovascular Angiography and Interventions and the Society of Thoracic Surgeons. J Am Coll Cardiol 2010; 56 (04) 321-341
    CrossrefPubMedGoogle Scholar
  • 57 Mega JL, Close SL, Wiviott SD. , et al. Cytochrome P450 genetic polymorphisms and the response to prasugrel: relationship to pharmacokinetic, pharmacodynamic, and clinical outcomes. Circulation 2009; 119 (19) 2553-2560
    CrossrefPubMedGoogle Scholar
  • 58 Hochholzer W, Trenk D, Fromm MF. , et al. Impact of cytochrome P450 2C19 loss-of-function polymorphism and of major demographic characteristics on residual platelet function after loading and maintenance treatment with clopidogrel in patients undergoing elective coronary stent placement. J Am Coll Cardiol 2010; 55 (22) 2427-2434
    CrossrefPubMedGoogle Scholar
  • 59 Alexopoulos D, Dimitropoulos G, Davlouros P. , et al. Prasugrel overcomes high on-clopidogrel platelet reactivity post-stenting more effectively than high-dose (150-mg) clopidogrel: the importance of CYP2C19*2 genotyping. JACC Cardiovasc Interv 2011; 4 (04) 403-410
    CrossrefPubMedGoogle Scholar
  • 60 Collet JP, Hulot JS, Anzaha G. , et al; CLOVIS-2 Investigators. High doses of clopidogrel to overcome genetic resistance: the randomized crossover CLOVIS-2 (Clopidogrel and Response Variability Investigation Study 2). JACC Cardiovasc Interv 2011; 4 (04) 392-402
    CrossrefPubMedGoogle Scholar
  • 61 Pereira NL, Sargent DJ, Farkouh ME, Rihal CS. Genotype-based clinical trials in cardiovascular disease. Nat Rev Cardiol 2015; 12 (08) 475-487
    CrossrefPubMedGoogle Scholar
  • 62 Collet JP, Hulot JS, Cuisset T. , et al; ARCTIC investigators. Genetic and platelet function testing of antiplatelet therapy for percutaneous coronary intervention: the ARCTIC-GENE study. Eur J Clin Pharmacol 2015; 71 (11) 1315-1324
    CrossrefPubMedGoogle Scholar
  • 63 Sibbing D, Gross L. CYP2C19 genotyping in percutaneous coronary intervention-treated patients: ready for prime time?. JACC Cardiovasc Interv 2018; 11 (02) 192-194
    CrossrefPubMedGoogle Scholar
  • 64 Notarangelo FM, Maglietta G, Bevilacqua P. , et al. Pharmacogenomic approach to selecting antiplatelet therapy in patients with acute coronary syndromes: the PHARMCLO Trial. J Am Coll Cardiol 2018; 71 (17) 1869-1877
    CrossrefPubMedGoogle Scholar
  • 65 Price MJ, Angiolillo DJ. Pharmacogenomic testing to select antiplatelet therapy. J Am Coll Cardiol 2018; 71 (17) 1878-1881
    CrossrefPubMedGoogle Scholar